Cytotoxic chemotherapy: clinical aspects

Medicine

Volumn 36, Issue 1, 2008, Pages 24-28

  Corrie, Pippa G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

application; cancer; cancer treatment; chemotherapy; cytotoxic agents

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CAPECITABINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID ANTAGONIST; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PREDNISOLONE; PROCARBAZINE; PYRIDOXINE; RALTITREXED; TAXANE DERIVATIVE; UFT; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FATIGUE; HAIR LOSS; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; INFERTILITY; INTESTINE CANCER; KIDNEY FAILURE; LETHARGY; LUNG FIBROSIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL DYSTROPHY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ORAL MUCOSAL DISEASE; OTOTOXICITY; OVARY CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SIDE EFFECT; SKIN EXFOLIATION; SOLID TUMOR; SUBFERTILITY; TERATOGENICITY; THROMBOCYTOPENIA; VOMITING;

EID: 37749036552     PISSN: 13573039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpmed.2007.10.012     Document Type: Review

References (16)

1. Clark P. Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomised controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group. Lancet 359 (2002) 1727-1733
2. Travis L.B., Rabkin C.S., Brown L.M., et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 98 (2006) 15-25
3. Allan J.M., and Travis L.B. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5 (2005) 943-955
4. Matesich S.M., and Shapiro C.L. Second cancers after breast cancer treatment. Semin Oncol 30 (2003) 740-748
5. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. New Eng Med J 355 (2006) 1572-1582
6. National Institute for Health and Clinical Excellence. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer. Technology Appraisal 61 (May 2003), NICE, London
7. National Institute for Clinical Excellence. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer. Technology Appraisal 62 (May 2003), NICE, London
8. Weingart S.N., Flug J., Brouillard D., et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 334 (2007) 407-409
9. Department of Health. National guidance on the safe administration of intrathecal chemotherapy (Oct 2003), DoH, London. http://www.dh.gov.uk (HSC 2003/010). Available at:
10. Hamilton C.A., and Berek J.S. Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol 18 (2006) 507-515
11. Kerr D.J., McArdle C.S., Ledermann J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361 (2003) 368-373
12. Nobili S., Landini I., Giglioni B., and Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7 (2006) 861-879
13. Quintieri L., Fantin M., and Vizler C. Identification of molecular determinants of tumour sensitivity and resistance to anticancer drugs. Adv Exp Med Biol 593 (2007) 95-104
14. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
15. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cell. Nature 414 (2001) 105-111
16. Yilmaz O.H., Valdez R., Theisen B.K., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482